Dyne Therapeutics Announces Positive Cardiopulmonary Results from DMD Trial

New analyses show improvement in heart and lung function with z-rostudirsen treatment

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Dyne Therapeutics has announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The new analyses out to 24 months showed improvement in heart and lung function compared to expected declines in DMD natural history.

Why it matters

Cardiopulmonary issues are a major concern in DMD, so the improvements in heart and lung function observed with z-rostudirsen treatment are particularly encouraging. These results suggest the potential for z-rostudirsen to provide broad functional benefits beyond just muscle function for individuals with DMD.

The details

The new analyses showed improvement from baseline in lung function, as measured by Forced Vital Capacity Percent Predicted (FVC%p), through 24 months, compared to the expected decline in natural history data. Improvement was also observed in circumferential strain, an early signal of cardiac performance, and in left ventricular ejection fraction, a measure of how well the heart is pumping, at 24 months, in contrast with the expected decline in natural history data.

  • The DELIVER trial is a global, randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial.
  • The placebo-controlled portion of the registrational expansion cohort (REC) to support a potential regulatory submission for U.S. Accelerated Approval has been completed.

The players

Dyne Therapeutics, Inc.

A clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.

Doug Kerr, M.D., Ph.D.

Chief medical officer of Dyne.

zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251)

An investigational therapeutic being evaluated in the DELIVER trial for individuals with DMD who have mutations amenable to exon 51 skipping.

Duchenne muscular dystrophy (DMD)

A rare X-linked progressive neuromuscular disorder caused by mutations in the DMD gene, affecting approximately 12,000 individuals in the U.S. and 16,000 in the EU.

Got photos? Submit your photos here. ›

What they’re saying

“This week we are presenting additional analyses of 24-month data from the DELIVER trial showing the breadth of potential benefits z-rostudirsen may bring to individuals with exon 51 skip amenable DMD beyond the previously reported unprecedented improvements in muscle function.”

— Doug Kerr, Chief medical officer of Dyne (Globe Newswire)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

These data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures in DMD, including key cardiopulmonary outcomes, highlighting the potential of Dyne's FORCE platform to deliver therapeutics to a broad range of muscles.